Navigation Links
United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
Date:10/28/2010

SILVER SPRING, Md., Oct. 28 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2010.

Total revenues for the third quarter of 2010 were $171.0 million, up from $97.2 million for the same quarter in 2009. Net income for the third quarter of 2010 was $39.7 million, or $0.70 per basic share, compared to net income of $11.9 million, or $0.22 per basic share, for the same quarter in 2009. Gross margin from sales was $148.9 million for the third quarter of 2010, compared to $84.2 million for the same quarter last year. Earnings before non-cash charges, a non-GAAP financial measure(1), was $99.1 million for the third quarter of 2010 compared to $40.6 million for the third quarter of 2009.  

"We had a good quarter as the demand for our core products continues to grow," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "Having approvals for multiple products is making a positive difference in our growth rate and in the number of patients that we can help compared to last year."

(1) See definition of earnings before non-cash charges and a reconciliation of net income to earnings before non-cash charges below.

Financial Results for the Three Months Ended September 30, 2010RevenuesThe following table sets forth the components of net revenues (dollars in thousands):Three Months Ended
September 30,20102009Percentage Change Cardiopulmonary products:Remodulin$

109,584$

87,40025.4%Tyvaso48,7175,113852.8%Adcirca9,9351,514556.2%Telemedicine services and products2,4082,904(17.1)%Other33928419.4%Total net revenues$

170,983$

97,21575.9%The growth in revenues for the three months ended September 30, 2010 reflects the continued increase in the number of patients being prescribed our products. The increase in sales of Remodulin also reflects approximately $9.1 million from the impact of U.S. and international price increases that became effective during March and April of 2010.

Research and Development ExpenseThe table below summarizes research and development expense by major project and non-project component (dollars in thousands):Three Months Ended
September 30,20102009PercentageChangeProject and non-project component:Cardiopulmonary $

17,510$

14,14523.8%Share-based compensation14,14911,57722.2%Other9,0325,82954.9%Total research and development expense$

40,691$

31,55129.0%Cardiopulmonary. The increase in expenses related to our cardiopulmonary programs for the quarter ended September 30, 2010 compared to the same quarter in 2009 was driven largely by increases in expenses associated with our FREEDOM-M and FREEDOM-C2 Phase III clinical trials and expenses related to our efforts to develop beraprost-MR.

Share-based compensation. The increase in share-based compensation for the quarter ended September 30, 2010 compared to the same quarter in 2009 resulted from increases in the price of our common stock, the number of outstanding awards issued under our share tracking awards plan and the time such awards had accrued toward vesting.

Other. For the quarter ended September 30, 2010, expenses incurred in connection with our investigational projects as well as personnel and overhead costs supporting our research increased primarily as a result of the opening of our new facilities in North Carolina and Maryland.

Selling, General and Administrative ExpenseThe table below summarizes selling, general and administrative expense by major category (dollars in thousands):Three Months Ended
September 30,20102009Percentage
ChangeCategory:General and administrative$

18,454$

15,36920.1%Sales and marketing11,06412,224(9.5)%Share-based compensation17,17113,57926.5%Total selling, general and administrative expense$

46,689$

41,17213.4%General and administrative. The increase in general and administrative expenses for the quarter ended September 30, 2010 compared to the same quarter in 2009 resulted largely from increases in the following: (1) grants to unaffiliated, not-for-profit organizations that provide therapy-related financial assistance to patients suffering from pulmonary arterial hypertension; (2) professional fees pertaining mainly to legal services provided in connection with ongoing litigation and prospective transactions; and (3) depreciation expense primarily associated with our new facilities in North Carolina and Maryland.

Sales and marketing. The decrease in sales and marketing expenses for the quarter ended September 30, 2010 compared to the same quarter in 2009 was attributable to a reduction in advertising and professional services. Marketing-related expenses were higher during the same quarter in 2009 as a result of our activities surrounding the commercial launch of Adcirca and Tyvaso.  

Share-based compensation. The increase in share-based compensation for the quarter ended September 30, 2010 compared to the same quarter in 2009 resulted from increases in the price of our common stock, the number of outstanding awards issued under our share tracking awards plan and the time such awards had accrued toward vesting.

Income taxes. The provision for income taxes was $18.0 million for the quarter ended September 30, 2010, compared to a $2.9 million benefit for the same quarter in 2009. The estimated annual effective tax rate was approximately 36 percent and 19 percent as of September 30, 2010 and 2009, respectively.  For the three months ended September 30, 2010, we had a higher projection of pre-tax earnings, as well as a lower estimate of business tax credits expected to be generated compared to the same period in 2009. These factors increased the estimated annual effective tax rate for the three months ended September 30, 2010 when compared to the same period in 2009.

Earnings before Non-Cash Charges Earnings before non-cash charges is defined as net income, adjusted for the following non-cash charges, as applicable: (i) interest; (ii) income taxes; (iii) license fees; (iv) depreciation and amortization; (v) impairment charges; and (vi) share-based compensation (stock option and share tracking award expense).

The following table provides a reconciliation of net income to earnings before non-cash charges for each of the quarters ended September 30, 2010 and 2009 (in thousands, except per share data):Three Months Ended
September 30,20102009Net income, as reported$

39,736$

11,937Adjust for non-cash charges:Interest expense4,8093,331Income tax expense (benefit)17,998(2,891)License fees --Depreciation and amortization5,0282,505Impairment charges-399Share-based compensation31,50025,293Earnings before non-cash charges$

99,071$

40,574Earnings before non-cash charges per share(1):Basic$

1.75$

0.76Diluted$

1.65$

0.70(1) Calculated by dividing earnings before non-cash charges by the basic and diluted weighted average number of common shares outstanding, as reported below in our Consolidated Statements of Operations.Conference CallWe will host a half-hour teleconference on Thursday, October 28, 2010 at 9:00 a.m. Eastern Time.  The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291, and using conference code: 14787030.

This teleconference is also being webcast and can be accessed via our website at http://ir.unither.com/events.cfm.

About United TherapeuticsUnited Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Non-GAAP Financial InformationThis press release contains a financial measure (earnings before non-cash charges) that does not comply with United States generally accepted accounting principles (GAAP). This measure supplements our financial results prepared in accordance with GAAP as reported below.

We use earnings before non-cash charges to assist us in: (a) planning, including the preparation of our internal annual operating budget; (b) allocating resources to enhance the financial performance of our business; (c) evaluating the effectiveness of our operational strategies; and (d) evaluating our capacity to fund capital expenditures and expand our business. We believe this non-GAAP financial measure enhances investors' understanding of our financial results by excluding certain expenses that we do not consider when evaluating and comparing the performance of our core operations and making operating decisions. In addition, we have historically reported earnings before non-cash charges to investors, and believe the inclusion of this non-GAAP financial measure provides investors with a consistent method of comparison to historical periods. However, there are limitations in the use of this non-GAAP financial measure as it excludes certain operating expenses that are recurring in nature and our calculation of this non-GAAP financial measure may differ from the methodology used by other companies. The presentation of this non-GAAP financial measure should not to be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. A reconciliation of net income, the most directly comparable GAAP financial measure, to earnings before non-cash charges can be found in the table above under the heading, Earnings before Non-Cash Charges.

Forward-looking StatementsStatements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations about operating results and demand for our products. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 28, 2010 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

Remodulin and Tyvaso are registered trademarks of United Therapeutics Corporation.

Adcirca is a registered trademark of Eli Lilly and Company.

UNITED THERAPEUTICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)Three Months Ended
September 30,Nine Months Ended
September 30,2010200920102009(Unaudited)(Unaudited)Revenues:Net product sales$

168,302$

94,058$

428,436$

251,925Service sales2,3422,8768,0158,054License fees339281903946Total revenues170,98397,215437,354260,925Operating expenses:Research and development40,69131,551104,50681,156Selling, general and administrative46,68941,172124,602119,761Cost of product sales20,16911,57649,18028,657Cost of service sales1,5531,1794,1123,168Total operating expenses109,10285,478282,400232,742Income from operations61,88111,737154,95428,183Other (expense) income:Interest income5641,0852,3104,141Interest expense(4,809)(3,331)(14,255)(9,216)Equity loss in affiliate(39)(42)(130)(99)Other, net137(403)455491Total other (expense) income, net(4,147)(2,691)(11,620)(4,683)Income before income tax57,7349,046143,33423,500Income tax (expense) benefit(17,998)2,891(46,962)(708)Net income $

39,736$

11,937$

96,372$

22,792Net income per common share:Basic$

0.70$

0.22$

1.73$

0.43Diluted$

0.66$

0.21$

1.62$

0.41Weighted average number of common shares outstanding:Basic56,53653,45555,79053,108Diluted60,21657,65359,54555,297CONSOLIDATED BALANCE SHEET DATA
September 30, 2010
(unaudited, in thousands)Cash, cash equivalents and marketable securities (excluding restricted amounts of $40,271)

$

625,906Total assets

$

1,282,784Total liabilities and common stock subject to repurchase

$

442,053Total stockholders' equity

$

840,731
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
5. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
6. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
7. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
8. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
9. United Therapeutics Reports Third Quarter 2008 Financial Results
10. Lilly Contributes $11.1 Million to United Way Annual Campaign
11. First United Kingdom Patients Treated With Percutaneous MitraClip(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Inc. (NASDAQ: NBIX ) today announced its financial results for ... --> --> For the fourth quarter of ... $0.34 loss per share, compared to a net loss of $19.4 ... 2014. For the year ended December 31, 2015, the Company reported ... as compared to a net loss of $60.5 million, or $0.81 ...
(Date:2/11/2016)... and GERMANTOWN, Maryland , ... Frankfurt Prime Standard: QIA) today announced the introduction of ... gene expression profiling, expanding QIAGEN,s portfolio of Sample to ... researchers to select from over 20,000 human genes and ... between genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Spectra BioPharma ... Organization (CSO) that provides biopharma companies the experience, ... implement and deploy outsourced sales teams. Created in ... team addresses both the strategic and tactical needs ... innovative sales solutions through both personal and non-personal ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... dedicated to delivering cutting-edge information focused on the development and manufacture of ... become a premier sponsor of the 2016 BioProcess International Awards – Recognizing ...
Breaking Biology Technology:
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):